METHYL 4-BROMO-2,2-DIMETHYL-3-OXOBUTANOATE, 95.0%, 250mg

(R)-Methyl 4-benzyl-5-oxomorpholine-3-carboxylate, 95.0%, 1g

8-Bromo-2,3-dihydro-1,4-benzodioxine-6-carbaldehyde, 97%, 500mg

(2-Chloro-4-formylphenyl)boronic acid, 95.0%, 250mg

2-Chloro-5-(trifluoromethyl)nicotinaldehyde, 95.0%, 10g

1,2-Epoxyhexane>96.0%(GC)25mL

TERT-BUTYL 1-OXA-4,8-DIAZASPIRO[5.5]UNDECANE-4-CARBOXYLATE, 95.0%, 100mg

4-(Propargyloxy)benzaldehyde>98.0%(GC)1g

1-(2,6-Dichlorophenyl)ethanamine hydrochloride, 95.0%, 250mg

tert-Butyl (4-(hydroxymethyl)pyridin-2-yl)carbamate, 95.0%, 25g

Long working distance plan phase 4x/0.13 IOS objective, working distance 10.75 mm

6-Bromo-7-fluoroisoquinolin-1(2H)-one, 97%, 250mg

1-tert-butyl-4-isopropyl-1,6-dihydro-7H-pyrazolo[3,4-d]pyridazin-7-one, 95.0%, 2.5g